title: Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors.
authors.affiliation: Institute of Pharmaceutical Medicine/ECPM, University Basel, Basel, Switzerland. klazien.matter@unibas.ch.|SAKK Coordinating Centre, Bern, Switzerland. klazien.matter@unibas.ch.
authors.forename: K
authors.initials: K
authors.lastname: Matter-Walstra
authors.affiliation: Department Dermatology, University Hospital Zürich, Zürich, Switzerland.
authors.forename: R
authors.initials: R
authors.lastname: Braun
authors.affiliation: SAKK Coordinating Centre, Bern, Switzerland.
authors.forename: C
authors.initials: C
authors.lastname: Kolb
authors.affiliation: Institute of Pharmaceutical Medicine/ECPM, University Basel, Basel, Switzerland.
authors.forename: Z
authors.initials: Z
authors.lastname: Ademi
authors.affiliation: Department Dermatology, University Hospital Zürich, Zürich, Switzerland.
authors.forename: R
authors.initials: R
authors.lastname: Dummer
authors.affiliation: SAKK Coordinating Centre, Bern, Switzerland.|Department Oncology, University Hospital Zürich, Zürich, Switzerland.
authors.forename: B C
authors.initials: BC
authors.lastname: Pestalozzi
authors.affiliation: Institute of Pharmaceutical Medicine/ECPM, University Basel, Basel, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Schwenkglenks
mesh_terms: D003362:Cost-Benefit Analysis; D006801:Humans; D008545:Melanoma; D012878:Skin Neoplasms